Peter Stastny
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peter Stastny has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Yizhou Zou
Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA
11 shared publicationsBhavna Lavingia
UT Southwestern Medical Center
6 shared publicationsDaria Perez Alonso
University of Texas Southwestern Medical Center
2 shared publicationsDavid E. Fixler
2 shared publicationsY. Zou
Department of Internal Medicine University of Texas Southwestern Medical Center Dallas TX USA
2 shared publicationsYisun Fan
2 shared publications
Latest Publications
- 4 December 2012
- Published by Wiley in International Journal of Immunogenetics
- Vol. 40 (1) , 11-16
16th IHIW: Report of the MICA Project
Summary: The MICA Project of the 16th International HLA and Immunogenetics Workshop was planned to improve the detection of specific antibodies against MICA antigens that develop in organ transplant recipients. It was organized as a serum exchange with 18 laboratories located in seven countries as participants. Each laboratory used the MICA screening reagents available to them. It was found that there were four different kits of Luminex beads conjugated with MICA antigens that could be used in these experiments. They were, kit BL, produced by Rainer Blasczyk in Hannover, Germany, containing 12 MICA antigens, the kit from Gen‐Probe (GP), which included 28 MICA antigens, the beads from One Lambda (OL), consisting of ten antigens, and the beads produced in the laboratory of the organizers (ZS) consisting of 11 MICA antigens. The sera were all from transplant recipients and represented a spectrum of MICA‐specific antibodies that are commonly found. All laboratories accurately could recognize which sera contained MICA antibodies. None failed to recognize the negative serum that was included in one of the shipments. While there were important differences in the specificities of MICA antigens recognized by the different kits, the results in laboratories using the same beads were remarkably similar. Feedback was given to the participants, and especially to the producers of the antibody detection kits, after each set of four sera was sent, and results were collected. Certain beads were replaced and results improved as can be seen in the results of the third shipment of sera. It is important for laboratories to be able to accurately determine the specificity of antibodies against MICA to know whether the antibodies are donor specific. Although complete consensus was not attained, some important errors were corrected, and a better understanding of how to accurately determine MICA allele–specific antibodies was developed.
- 4 December 2012
- Published by Wiley in International Journal of Immunogenetics
- Vol. 40 (1) , 11-16
16th IHIW: Report of the MICA Project
Summary: The MICA Project of the 16th International HLA and Immunogenetics Workshop was planned to improve the detection of specific antibodies against MICA antigens that develop in organ transplant recipients. It was organized as a serum exchange with 18 laboratories located in seven countries as participants. Each laboratory used the MICA screening reagents available to them. It was found that there were four different kits of Luminex beads conjugated with MICA antigens that could be used in these experiments. They were, kit BL, produced by Rainer Blasczyk in Hannover, Germany, containing 12 MICA antigens, the kit from Gen‐Probe (GP), which included 28 MICA antigens, the beads from One Lambda (OL), consisting of ten antigens, and the beads produced in the laboratory of the organizers (ZS) consisting of 11 MICA antigens. The sera were all from transplant recipients and represented a spectrum of MICA‐specific antibodies that are commonly found. All laboratories accurately could recognize which sera contained MICA antibodies. None failed to recognize the negative serum that was included in one of the shipments. While there were important differences in the specificities of MICA antigens recognized by the different kits, the results in laboratories using the same beads were remarkably similar. Feedback was given to the participants, and especially to the producers of the antibody detection kits, after each set of four sera was sent, and results were collected. Certain beads were replaced and results improved as can be seen in the results of the third shipment of sera. It is important for laboratories to be able to accurately determine the specificity of antibodies against MICA to know whether the antibodies are donor specific. Although complete consensus was not attained, some important errors were corrected, and a better understanding of how to accurately determine MICA allele–specific antibodies was developed.
- 31 August 2012
- Published by Elsevier in Human Immunology
- Vol. 73, 40
49-OR
- 26 April 2012
- Published by Springer Nature
- Vol. 882, 279-288
Screening for Antibodies Against MICA by Luminex Flow Cytometry
Antibodies against MICA have been found in organ transplant recipients and were found to be associated with decreased survival of kidney allografts. The MICA antibody screening assay is a Luminex-based solid phase immunoassay designed to detect IgG antibodies binding to beads pre-coated with recombinant preparations of MICA alleles. These beads coated with soluble MICA recombinant proteins including 11 common alleles have been produced in our laboratory and similar preparations have been available from commercial sources. Here, we describe the procedure of MICA antibody screening with a prepared kit, in which all the reagents were optimized and standardized. We also review how to document the quality of single MICA antigen beads using MICA-specific monoclonal antibodies, as well as quality control of the procedure and data analysis.
- 26 April 2012
- Published by Springer Nature
- Vol. 882, 279-288
Screening for Antibodies Against MICA by Luminex Flow Cytometry
Antibodies against MICA have been found in organ transplant recipients and were found to be associated with decreased survival of kidney allografts. The MICA antibody screening assay is a Luminex-based solid phase immunoassay designed to detect IgG antibodies binding to beads pre-coated with recombinant preparations of MICA alleles. These beads coated with soluble MICA recombinant proteins including 11 common alleles have been produced in our laboratory and similar preparations have been available from commercial sources. Here, we describe the procedure of MICA antibody screening with a prepared kit, in which all the reagents were optimized and standardized. We also review how to document the quality of single MICA antigen beads using MICA-specific monoclonal antibodies, as well as quality control of the procedure and data analysis.
- 26 April 2012
- Published by Springer Nature
- Vol. 882, 183-195
High Resolution MICA Genotyping by Sequence-Based Typing (SBT)
We have developed a MICA typing method based on polymerase chain reaction (PCR) sequence-based typing and a computer program that determines the polymorphisms and distinguishes the GCT repeats in exon 5. One PCR amplification was performed to obtain templates of 2.2 kb, including exons 2, 3, 4, and 5 of MICA to be sequenced with two forward and two reverse primers. Overlay of nucleotide sequencing signals resulting from presence of different GCT repeats in exon 5 from two different MICA alleles can be identified by a computer program that analyses the combined signal string containing the 35 bases.
- 26 April 2012
- Published by Springer Nature
- Vol. 882, 183-195
High Resolution MICA Genotyping by Sequence-Based Typing (SBT)
We have developed a MICA typing method based on polymerase chain reaction (PCR) sequence-based typing and a computer program that determines the polymorphisms and distinguishes the GCT repeats in exon 5. One PCR amplification was performed to obtain templates of 2.2 kb, including exons 2, 3, 4, and 5 of MICA to be sequenced with two forward and two reverse primers. Overlay of nucleotide sequencing signals resulting from presence of different GCT repeats in exon 5 from two different MICA alleles can be identified by a computer program that analyses the combined signal string containing the 35 bases.
- 1 November 2011
- Published by Springer Nature in Pediatric Nephrology
- Vol. 26 (11) , 1927-1935
Evaluation of the highly sensitized transplant recipient
The immune response against alloantigens involves the production of antibodies and development of T-cell immunity. Recipients sensitized to HLA antigens may have antibodies to almost all donors and may not be able to find a suitable kidney transplant donor. Strategies available to enable these patients to obtain a transplant are to give priority to highly sensitized patients, to perform therapy for antibody reduction or to transplant with existing antibodies and to intervene as needed with post-transplant treatment. While sensitization against HLA antigens is the most important cause of immunological transplant failure, other types of alloantigens, many of them expressed selectively in endothelial cells, and autoantigens may also be involved. Molecular typing and solid-phase antibody testing have markedly changed this field in the last few years. Methods for the analysis of HLA antibodies and for the study of T-cell reactivity and sensitization will also be discussed. Virtual cross-matching can now be performed for many patients, resulting in considerable savings in time and effort. Successful application of this approach requires the intervention of highly trained personnel with a good understanding of the limitations of the procedure and with intimate knowledge of the antibody profiles of the patients on the waiting list.
- 1 November 2011
- Published by Springer Nature in Pediatric Nephrology
- Vol. 26 (11) , 1927-1935
Evaluation of the highly sensitized transplant recipient
The immune response against alloantigens involves the production of antibodies and development of T-cell immunity. Recipients sensitized to HLA antigens may have antibodies to almost all donors and may not be able to find a suitable kidney transplant donor. Strategies available to enable these patients to obtain a transplant are to give priority to highly sensitized patients, to perform therapy for antibody reduction or to transplant with existing antibodies and to intervene as needed with post-transplant treatment. While sensitization against HLA antigens is the most important cause of immunological transplant failure, other types of alloantigens, many of them expressed selectively in endothelial cells, and autoantigens may also be involved. Molecular typing and solid-phase antibody testing have markedly changed this field in the last few years. Methods for the analysis of HLA antibodies and for the study of T-cell reactivity and sensitization will also be discussed. Virtual cross-matching can now be performed for many patients, resulting in considerable savings in time and effort. Successful application of this approach requires the intervention of highly trained personnel with a good understanding of the limitations of the procedure and with intimate knowledge of the antibody profiles of the patients on the waiting list.
- 1 March 2011
- Vol. 124 (5) , 764-70
Antibodies against major histocompatibility complex class I-related chain A in transplant recipients.
To review the role of polymorphism of major histocompatibility complex class I-related chain A (MICA) gene and antibodies against MICA antigens in transplant immunology. The data used in this review were mainly from our own results and from the relevant English language literatures published from 1999 to 2010. Some data presented in this review are in press. Articles regarding MICA gene discovery and pioneering finding of antibodies against MICA antigen and allograft rejection were selected. This review chronicles the development of our understanding of the role that MICA antigens and antibodies may play in organ transplantation. Polymorphic glycoprotein MICA antigens were detected on freshly isolated human umbilical cord endothelial cells, but not on peripheral lymphocytes. Antibodies were found and typing of recipients and donors by sequencing the MICA alleles has established that de novo antibodies produced in kidney transplant recipients are directed at mismatched MICA epitopes and are associated with acute rejection and chronic transplant failure. The specificity of antibodies against the epitopes of MICA antigens were well characterized by donor MICA typing, single antigen array testing with antibody absorption and elution. Acute graft-versus-host disease was observed in stem-cell recipients who were mismatched for MICA. Immunization against mismatched MICA epitopes encountered in donor organs after transplantation may result in antibodies against MICA alleles. Testing for MICA donor-specific antibodies (DSA) which are associated with early failure of kidney transplants may be helpful for identifying some of the targets of antibodies against antigens other than the human leukocyte antigen (HLA) and for improving transplantation outcome.
- 1 March 2011
- Vol. 124 (5) , 764-70
Antibodies against major histocompatibility complex class I-related chain A in transplant recipients.
To review the role of polymorphism of major histocompatibility complex class I-related chain A (MICA) gene and antibodies against MICA antigens in transplant immunology. The data used in this review were mainly from our own results and from the relevant English language literatures published from 1999 to 2010. Some data presented in this review are in press. Articles regarding MICA gene discovery and pioneering finding of antibodies against MICA antigen and allograft rejection were selected. This review chronicles the development of our understanding of the role that MICA antigens and antibodies may play in organ transplantation. Polymorphic glycoprotein MICA antigens were detected on freshly isolated human umbilical cord endothelial cells, but not on peripheral lymphocytes. Antibodies were found and typing of recipients and donors by sequencing the MICA alleles has established that de novo antibodies produced in kidney transplant recipients are directed at mismatched MICA epitopes and are associated with acute rejection and chronic transplant failure. The specificity of antibodies against the epitopes of MICA antigens were well characterized by donor MICA typing, single antigen array testing with antibody absorption and elution. Acute graft-versus-host disease was observed in stem-cell recipients who were mismatched for MICA. Immunization against mismatched MICA epitopes encountered in donor organs after transplantation may result in antibodies against MICA alleles. Testing for MICA donor-specific antibodies (DSA) which are associated with early failure of kidney transplants may be helpful for identifying some of the targets of antibodies against antigens other than the human leukocyte antigen (HLA) and for improving transplantation outcome.
- 9 June 2010
- Published by Wiley in Tissue Antigens
- Vol. 76 (3) , 171-176
Role of MICA in the immune response to transplants
Among the cell surface antigens that can elicit an immune response in transplant recipients MICA antigens occupy a special place. They are similar to human leukocyte antigens (HLAs) while being very different from them. They are not as polymorphic and their quantity is smaller. In consequence, the impact of MICA antigens in transplantation is not as dramatic. However, our early guess that these ligands of NKG2D could elicit antibodies and cell‐mediated immunity has been definitely confirmed. Careful analysis with MICA transfectant cells, for absorption and elution, established the specificity of the epitopes involved. Typing of recipients and donors by sequencing the MICA alleles has established that de novo antibodies produced in kidney transplant recipients are directed at mismatched MICA epitopes and are associated with acute rejection and chronic transplant failure. Acute graft‐versus‐host disease was observed in stem cell recipients who were mismatched for MICA.
- 9 June 2010
- Published by Wiley in Tissue Antigens
- Vol. 76 (3) , 171-176
Role of MICA in the immune response to transplants
Among the cell surface antigens that can elicit an immune response in transplant recipients MICA antigens occupy a special place. They are similar to human leukocyte antigens (HLAs) while being very different from them. They are not as polymorphic and their quantity is smaller. In consequence, the impact of MICA antigens in transplantation is not as dramatic. However, our early guess that these ligands of NKG2D could elicit antibodies and cell‐mediated immunity has been definitely confirmed. Careful analysis with MICA transfectant cells, for absorption and elution, established the specificity of the epitopes involved. Typing of recipients and donors by sequencing the MICA alleles has established that de novo antibodies produced in kidney transplant recipients are directed at mismatched MICA epitopes and are associated with acute rejection and chronic transplant failure. Acute graft‐versus‐host disease was observed in stem cell recipients who were mismatched for MICA.
- Open Access
- 30 January 2009
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 3 (1) , 41
Successful renal re-transplantation in the presence of pre-existing anti-DQ5 antibodies when there was zero mismatch at class I human leukocyte antigen A, B, & C: a case report
Introduction: Hyperacute rejection may be prevented by avoiding the transplantation of kidneys into patients with pre-existing anti-donor Class I human leukocyte antigen antibodies. However, the role of anti-donor-Class II-human leukocyte antigen-DQ antibodies is not established. The question is ever more relevant as more sensitive cross-matching techniques detect many additional antibodies during the final crossmatch. We now report successful renal transplantation of a patient who had pre-existing antibodies against his donor's human leukocyte antigen-DQ5.Case presentation: Our patient, a Caucasian man, was 34 years of age when he received his first deceased donor renal transplant. After 8 years, his first transplant failed from chronic allograft dysfunction and an earlier bout of Banff 1A cellular rejection. The second deceased donor kidney transplant was initially allocated to the patient due to a 0 out of 6 mismatch. The B cell crossmatch was mildly positive, while the T Cell crossmatch was negative. Subsequent assays showed that the patient had preformed antibodies for human leukocyte antigen DQ5 against his second donor. Despite having preformed antibodies against the donor, the patient continues to have excellent allograft function two years after his second renal transplant.Conclusion: The presence of pre-existing antibodies against human leukocyte antigen DQ5 does not preclude transplantation. The relevance of having other antibodies against class II human leukocyte antigens prior to transplantation remains to be studied.
- 30 January 2009
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 3 (1) , 41
Open AccessSuccessful renal re-transplantation in the presence of pre-existing anti-DQ5 antibodies when there was zero mismatch at class I human leukocyte antigen A, B, & C: a case report
Introduction: Hyperacute rejection may be prevented by avoiding the transplantation of kidneys into patients with pre-existing anti-donor Class I human leukocyte antigen antibodies. However, the role of anti-donor-Class II-human leukocyte antigen-DQ antibodies is not established. The question is ever more relevant as more sensitive cross-matching techniques detect many additional antibodies during the final crossmatch. We now report successful renal transplantation of a patient who had pre-existing antibodies against his donor's human leukocyte antigen-DQ5.Case presentation: Our patient, a Caucasian man, was 34 years of age when he received his first deceased donor renal transplant. After 8 years, his first transplant failed from chronic allograft dysfunction and an earlier bout of Banff 1A cellular rejection. The second deceased donor kidney transplant was initially allocated to the patient due to a 0 out of 6 mismatch. The B cell crossmatch was mildly positive, while the T Cell crossmatch was negative. Subsequent assays showed that the patient had preformed antibodies for human leukocyte antigen DQ5 against his second donor. Despite having preformed antibodies against the donor, the patient continues to have excellent allograft function two years after his second renal transplant.Conclusion: The presence of pre-existing antibodies against human leukocyte antigen DQ5 does not preclude transplantation. The relevance of having other antibodies against class II human leukocyte antigens prior to transplantation remains to be studied.
- 31 October 2008
- Published by Elsevier in Human Immunology
- Vol. 69, S132-132
62-W: Mismatches in DPB1, DQB1, DRB3/4/5 and MICA play a significant role in allogeneic HSC transplantation
- 31 October 2008
- Published by Elsevier in Human Immunology
- Vol. 69, S132-132
62-W: Mismatches in DPB1, DQB1, DRB3/4/5 and MICA play a significant role in allogeneic HSC transplantation
- 1 January 2008
- Published by S. Karger AG
- Vol. 162, 99-106
The Emerging Issue of MICA Antibodies: Antibodies to MICA and Other Antigens of Endothelial Cells
The major histocompatibility complex (MHC) encodes the HLA class I antigens expressed on the surface of most nucleated cells and the HLA class II antigens which are expressed mostly in B lymphocytes, monocytes and dendritic cells. Mismatched HLA anti-gens are the main source of the immune response that leads to the rejection of allografts. In some patients however, rejection may occur without a detectable response to donor HLA antigens. We have been interested in characterizing antibodies that develop in transplant recipients who do not appear to have antibodies against HLA. For this purpose, we focused our attention to antigens which are expressed on the surface of endothelial cells and are not found on peripheral blood lymphocytes. These include the MICA and MICB antigens, which are encoded by loci in the MHC; certain autoantigens expressed on the endothelium; and a family of polymorphic antigens expressed on endothelial cells which are distinct from HLA and elicit production of antibodies that appear also to be associated with graft failure. Antibodies against MICA have been associated with allograft rejection. MICB antibodies are only rarely found. The autoantibodies and the endothelial specific alloantibodies are being characterized in ongoing studies.
- 1 January 2008
- Published by S. Karger AG
- Vol. 162, 99-106
The Emerging Issue of MICA Antibodies: Antibodies to MICA and Other Antigens of Endothelial Cells
The major histocompatibility complex (MHC) encodes the HLA class I antigens expressed on the surface of most nucleated cells and the HLA class II antigens which are expressed mostly in B lymphocytes, monocytes and dendritic cells. Mismatched HLA anti-gens are the main source of the immune response that leads to the rejection of allografts. In some patients however, rejection may occur without a detectable response to donor HLA antigens. We have been interested in characterizing antibodies that develop in transplant recipients who do not appear to have antibodies against HLA. For this purpose, we focused our attention to antigens which are expressed on the surface of endothelial cells and are not found on peripheral blood lymphocytes. These include the MICA and MICB antigens, which are encoded by loci in the MHC; certain autoantigens expressed on the endothelium; and a family of polymorphic antigens expressed on endothelial cells which are distinct from HLA and elicit production of antibodies that appear also to be associated with graft failure. Antibodies against MICA have been associated with allograft rejection. MICB antibodies are only rarely found. The autoantibodies and the endothelial specific alloantibodies are being characterized in ongoing studies.